var data={"title":"Emery-Dreifuss muscular dystrophy","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Emery-Dreifuss muscular dystrophy</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/contributors\" class=\"contributor contributor_credentials\">Basil T Darras, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/contributors\" class=\"contributor contributor_credentials\">Marc C Patterson, MD, FRACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/contributors\" class=\"contributor contributor_credentials\">John F Dashe, MD, PhD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 08, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The muscular dystrophies are an inherited group of progressive myopathic disorders resulting from defects in a number of genes required for normal muscle function. Some of the genes responsible for these conditions have been identified. Muscle weakness is the primary symptom.</p><p>Emery-Dreifuss muscular dystrophy (EDMD), also known as humeroperoneal muscular dystrophy, can be inherited as an X-linked recessive, autosomal dominant, or autosomal recessive disorder.</p><p>The pathogenesis, genetics, and clinical characteristics of EDMD are discussed here. Other muscular dystrophies are presented separately. (See <a href=\"topic.htm?path=duchenne-and-becker-muscular-dystrophy-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Duchenne and Becker muscular dystrophy: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=myotonic-dystrophy-etiology-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Myotonic dystrophy: Etiology, clinical features, and diagnosis&quot;</a> and <a href=\"topic.htm?path=facioscapulohumeral-muscular-dystrophy\" class=\"medical medical_review\">&quot;Facioscapulohumeral muscular dystrophy&quot;</a> and <a href=\"topic.htm?path=limb-girdle-muscular-dystrophy\" class=\"medical medical_review\">&quot;Limb-girdle muscular dystrophy&quot;</a> and <a href=\"topic.htm?path=oculopharyngeal-distal-and-congenital-muscular-dystrophies\" class=\"medical medical_review\">&quot;Oculopharyngeal, distal, and congenital muscular dystrophies&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">GENETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>EDMD is a genetically heterogenous disorder with X-linked recessive, autosomal dominant, and autosomal recessive forms [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/1\" class=\"abstract_t\">1</a>]. Several forms are considered nuclear envelopathies because they are associated with mutations in genes encoding nuclear membrane proteins, including the EMD gene that encodes for emerin, the LMNA gene that encodes for lamin A and lamin C, and the SYNE1 and SYNE2 genes that encode for nesprin 1 and nesprin 2, respectively [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/2\" class=\"abstract_t\">2</a>]. The most common type is autosomal dominant EDMD caused by a heterozygous LMNA mutation, followed by X-linked EDMD caused by EMD or FHL1 mutations [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/3\" class=\"abstract_t\">3</a>]. There are only a few reports of autosomal recessive EDMD. In a high proportion of EDMD cases, the genetic defect remains unknown [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">X-linked forms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The X-linked forms of the disorder are EDMD1 and EDMD6:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The EMD gene on Xq28 (EDMD1) encodes emerin, a protein that is localized to the nuclear envelope [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/4-7\" class=\"abstract_t\">4-7</a>]. Most mutations are null mutations resulting in complete loss of emerin expression in muscle. Missense mutations are associated with decreased or even normal amounts of emerin and result in a milder phenotype.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The FHL1 gene on Xq26.3 (EDMD6) encodes the four-and-a-half LIM domains protein 1 and is associated with an X-linked EDMD phenotype with hypertrophic cardiomyopathy [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/8,9\" class=\"abstract_t\">8,9</a>]. Mutations in the FHL1 gene result in delayed myotube formation [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p>The nomenclature and classification of FHL1-linked <span class=\"nowrap\">myopathies/muscular</span> dystrophies is still evolving. In addition to EDMD6, FHL1 mutations have also been identified in patients with X-linked myopathy with postural muscle atrophy, X-linked dominant scapuloperoneal myopathy, X-linked reducing body myopathy with early childhood onset, and myofibrillar myopathy [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/10,11\" class=\"abstract_t\">10,11</a>]. Common features of FHL1 disorders include joint contractures, spinal rigidity, and cardiac involvement. Reducing body aggregates in muscle biopsies are a characteristic feature of reducing body myopathy and scapuloperoneal myopathy. In contrast, muscle biopsies of patients with EDMD6 do not show reducing bodies, but the expression of FHL1A protein is moderately to severely decreased [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/8\" class=\"abstract_t\">8</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Autosomal dominant and recessive forms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both an autosomal dominant (EDMD2) and a rare autosomal recessive (EDMD3) form are linked to mutations of the LMNA gene on chromosome 1q21.2 that encodes for lamin A and lamin C, two A-type lamins found in the nuclear envelope [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/12-14\" class=\"abstract_t\">12-14</a>].</p><p>Other EDMD-like phenotypes with autosomal dominant inheritance are linked to mutations of SYNE1 (EDMD4) and SYNE2 (EDMD5), both of which encode for nuclear envelope proteins [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/1,15\" class=\"abstract_t\">1,15</a>]. However, the number of reported cases is small and thus the muscle phenotype remains to be defined.</p><p>Mutations in the TMEM43 gene, which encodes another nuclear envelope protein called LUMA, are also associated with an autosomal dominant EDMD-like phenotype (EDMD7) [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/16\" class=\"abstract_t\">16</a>]. Such mutations were found in 2 of 41 patients with EDMD-related myopathy. As with SYNE1 and SYNE2, additional data are needed to further delineate the phenotype of TMEM43-related myopathy [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Laminopathies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to EDMD2 and EDMD3, a number of other laminopathies (ie, disorders caused by LMNA gene mutations) have been identified [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/18\" class=\"abstract_t\">18</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Limb-girdle muscular dystrophy with atrioventricular conduction defects (LGMD1B)&nbsp;(see <a href=\"topic.htm?path=limb-girdle-muscular-dystrophy\" class=\"medical medical_review\">&quot;Limb-girdle muscular dystrophy&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Autosomal dominant dilated cardiomyopathy with conduction defects (CMD1A or DCM-CD) [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/19,20\" class=\"abstract_t\">19,20</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Autosomal dominant dilated cardiomyopathy with apical left ventricular aneurysm [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/21\" class=\"abstract_t\">21</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Autosomal dominant quadriceps myopathy with dilated cardiomyopathy and associated conduction defects [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/22\" class=\"abstract_t\">22</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A relatively severe form of congenital muscular dystrophy classified as LMNA-related congenital muscular dystrophy [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/23-25\" class=\"abstract_t\">23-25</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Charcot-Marie-Tooth type 2B1 [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/26\" class=\"abstract_t\">26</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Familial partial lipodystrophy type 2 (see <a href=\"topic.htm?path=lipodystrophic-syndromes#H14\" class=\"medical medical_review\">&quot;Lipodystrophic syndromes&quot;, section on 'FPLD type 2'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mandibuloacral dysplasia (see <a href=\"topic.htm?path=lipodystrophic-syndromes#H17\" class=\"medical medical_review\">&quot;Lipodystrophic syndromes&quot;, section on 'Mandibuloacral dysplasia'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hutchinson-Gilford progeria syndrome [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/27\" class=\"abstract_t\">27</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dilated cardiomyopathy and hypergonadotropic hypogonadism (atypical Werner syndrome) [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/28\" class=\"abstract_t\">28</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Restrictive dermopathy (also known as tight skin contracture syndrome), a lethal neonatal laminopathy [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/29\" class=\"abstract_t\">29</a>]</p><p/><p>Several reports have found patients harboring mutations in both EDMD and LMNA genes [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/30,31\" class=\"abstract_t\">30,31</a>]. The clinical presentations included severe EDMD, a combination of Charcot-Marie-Tooth type 2 and EDMD, and isolated cardiomyopathy.</p><p>Mutations in both emerin and desmin genes were found in a patient with cardioskeletal myopathy [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H692738139\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>EDMD is an uncommon if not rare disorder, although its overall incidence and prevalence are not known [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/3\" class=\"abstract_t\">3</a>]. In a study from Northern England, the prevalence of genetically confirmed cases of EDMD was 0.33 per 100,000 [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/32\" class=\"abstract_t\">32</a>], whereas the estimated prevalence of all forms of EDMD is &ge;1 per 100,000 [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/33\" class=\"abstract_t\">33</a>]. </p><p class=\"headingAnchor\" id=\"H967340517\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The major features of EDMD are early contractures, slowly progressive humeroperoneal muscle <span class=\"nowrap\">weakness/wasting,</span> and cardiac disease with conduction defects, arrhythmias, and cardiomyopathy [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/1,34\" class=\"abstract_t\">1,34</a>]. The different forms of EDMD have generally similar symptoms, which usually begin in the first or second decade of life. However, the disease exhibits significant inter- and intra-familial variability with regard to age at onset, severity, and progression of the major manifestations [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/35\" class=\"abstract_t\">35</a>]. Cases of adult onset with slow progression have been observed.</p><p class=\"headingAnchor\" id=\"H967340544\"><span class=\"h2\">Symptoms and signs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Contractures at the elbows are noted early and are commonly the first manifestations of EDMD. Contractures of the posterior aspect of the neck, the entire spine, and the Achilles tendons also occur. Achilles tendon contractures are frequently associated with toe walking. Severe spine and leg contractures eventually may lead to loss of ambulation.</p><p>Muscle weakness and wasting has a humeroperoneal distribution; it typically begins in the arms, involving both the biceps and triceps, with relative preservation of the deltoid muscles. Subsequently, distal leg weakness with atrophy of the peroneal muscles is noted. In some cases, mild facial weakness may also be observed. The myopathy tends to be slowly progressive during the first three decades of life, but more rapid thereafter.</p><p>A dilated cardiomyopathy is seen in most patients with EDMD. It is typically associated with atrioventricular conduction abnormalities such as first-degree atrioventricular block, but also with sinus bradycardia or supraventricular tachycardia, which may be early signs of cardiac involvement [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/36\" class=\"abstract_t\">36</a>]. Other findings include atrial paralysis, atrial fibrillation, and atrial flutter; these are most common in EDMD1. Symptoms of hypoperfusion (syncope or near syncope) often result from infranodal or atrioventricular conduction block with the development of slow junctional rhythms, requiring pacemaker insertion [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/37-39\" class=\"abstract_t\">37-39</a>]. The onset of cardiac abnormalities is usually in the third decade of life but earlier onset has been observed [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/20\" class=\"abstract_t\">20</a>]. Sudden death may develop in patients not previously diagnosed because they have little or no skeletal myopathy [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/39\" class=\"abstract_t\">39</a>]. There is no correlation between the degree of neuromuscular involvement and the severity of cardiac abnormalities [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/40\" class=\"abstract_t\">40</a>]. Arrhythmogenic dilated cardiomyopathy, cardiac failure, and ventricular tachyarrhythmias are more common and more severe in autosomal dominant EDMD2 (due to LMNA mutations) [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/41,42\" class=\"abstract_t\">41,42</a>] but also occur in X-linked EDMD1 (caused by EMD mutations) [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/43\" class=\"abstract_t\">43</a>].</p><p class=\"headingAnchor\" id=\"H967340762\"><span class=\"h2\">Laboratory studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>EDMD is associated with abnormalities in serum creatine kinase (CK), electrocardiography (ECG), electromyography (EMG), muscle imaging, and muscle biopsy:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A modest elevation of serum CK concentration, rarely higher than a few hundred <span class=\"nowrap\">units/L,</span> is typical. Increases up to 20 times the upper limit of normal sometimes occur, but may be seen more often in the early stages of the disease. CK levels are not useful in the identification of carriers because, even in obligate carriers, they tend to be normal [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/44\" class=\"abstract_t\">44</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The ECG may show varying degrees of atrioventricular block, small T waves, and atrial arrhythmias.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The EMG usually displays myopathic features and may also reveal evidence of denervation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The muscle biopsy typically shows mild myopathic changes characterized by internal nuclei, variation in fiber size, focal connective tissue proliferation, and occasional necrotic fibers. Inflammatory changes have been noted in the muscle biopsies of some children (&le;2 years of age) with infantile LMNA myopathy [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/25\" class=\"abstract_t\">25</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Muscle immunohistochemistry will reveal absence of nuclear staining for emerin in approximately 95 percent of patients with X-linked EDMD [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/45\" class=\"abstract_t\">45</a>]. No EMD gene mutations have been detected in patients who were emerin-positive, which underscores the diagnostic value of muscle immunohistochemistry [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/42\" class=\"abstract_t\">42</a>]. Emerin can also be detected by immunofluorescence <span class=\"nowrap\">and/or</span> western blot testing in muscle and other tissues including skin, exfoliative buccal cells, lymphocytes, and lymphoblastoid cell lines [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/46,47\" class=\"abstract_t\">46,47</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with EDMD, leg muscle imaging reveals more severe changes in posterior calf muscles with selective involvement of the soleus in EDMD1 and of the medial gastrocnemius muscle in EDMD2; the MRI abnormalities are mild or moderate in other leg muscles [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/48\" class=\"abstract_t\">48</a>]. The pattern is similar in asymptomatic carriers and in patients with various phenotypes caused by LMNA gene mutations [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/49\" class=\"abstract_t\">49</a>]. The rectus femoris muscle is spared [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/49\" class=\"abstract_t\">49</a>].</p><p/><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical diagnosis of EDMD can be made for patients with the cardinal features:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Early contractures of elbow flexors, ankle plantar flexors, and spine</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Childhood onset of humeroperoneal weakness and wasting</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cardiac disease with conduction defects, arrhythmias, and cardiomyopathy </p><p/><p>In cases with typical clinical features of EDMD <span class=\"nowrap\">and/or</span> positive family history, genetic testing may avoid the need for EMG and muscle biopsy (<a href=\"image.htm?imageKey=NEURO%2F100447\" class=\"graphic graphic_algorithm graphicRef100447 \">algorithm 1</a>). Genetic testing should be ordered as the first diagnostic study in patients with a phenotype suggestive of EDMD since muscle biopsy is an invasive and less informative procedure [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/40\" class=\"abstract_t\">40</a>]. Electromyography and muscle biopsy are indicated in atypical cases, such as patients without a classic phenotype or lacking a family history.</p><p>In a male with a family history suggesting X-linked inheritance or those with no or unknown family history but a clinical presentation suggestive of EDMD, testing for EMD genetic mutations should be performed first, followed by genetic testing for the FHL1 gene if no EMD mutation is found. The proportion of cases with an EDMD phenotype and an X-linked inheritance pattern attributed to EMD gene mutations is approximately 60 percent, whereas the proportion attributed to FHL1 mutations is approximately 10 percent [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/8,17\" class=\"abstract_t\">8,17</a>]. For those without EMD or FHL1 mutations, testing can proceed to evaluate for mutations in LMNA, SYNE1, SYNE2, and TMEM43 gene mutations (<a href=\"image.htm?imageKey=NEURO%2F100447\" class=\"graphic graphic_algorithm graphicRef100447 \">algorithm 1</a>).</p><p>In a female, or any male with a clear family history of autosomal dominant or recessive inheritance, the LMNA gene should be screened first [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/40\" class=\"abstract_t\">40</a>], followed by testing for SYNE1, SYNE2, and TMEM43 gene mutations. In patients with autosomal dominant EDMD, gene sequence analysis or mutation scanning will detect LMNA sequence variants in about 45 percent of patients [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/17\" class=\"abstract_t\">17</a>]. Autosomal recessive EDMD has been reported in only a few individuals. Immunodetection of lamins <span class=\"nowrap\">A/C</span> is not a reliable diagnostic test because their expression is usually normal in patients with EDMD2 and EDMD3. (See <a href=\"#H7\" class=\"local\">'Autosomal dominant and recessive forms'</a> above.)</p><p>In sporadic or atypical cases where the etiology is not clear and family history is negative, the presence of myopathic or dystrophic changes on EMG and muscle biopsy is supportive not only of EDMD (<a href=\"image.htm?imageKey=PEDS%2F52444\" class=\"graphic graphic_algorithm graphicRef52444 \">algorithm 2</a>) but also various LGMDs. Emerin is absent from nuclei of skeletal muscle myocytes in X-linked EDMD. Thus, the diagnosis may be based upon immunohistologic examination of a muscle biopsy with confirmatory genetic testing for EMD mutations [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/50,51\" class=\"abstract_t\">50,51</a>]. The FHL1 gene should be screened if EMD gene testing is negative. Genetic testing for mutations in LMNA, FHL1, SYNE1, or SYNE2 genes is appropriate if nuclear staining for emerin is detectable and no EMD mutation is found (<a href=\"image.htm?imageKey=PEDS%2F52444\" class=\"graphic graphic_algorithm graphicRef52444 \">algorithm 2</a>), though SYNE1 or SYNE2-associated EDMD is quite rare.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other than the different inherited muscular dystrophies and myopathies, the differential diagnosis of EDMD includes the rigid spine syndrome (RSS). This disorder is usually associated with limited flexion of the spine, a relatively mild and slowly progressive myopathy, and elbow and ankle contractures [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/52\" class=\"abstract_t\">52</a>]. Some patients with RSS develop cor pulmonale with right heart involvement due to restrictive chest wall movement and respiratory muscle weakness [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/53\" class=\"abstract_t\">53</a>]. Early and severe scoliosis in the first decade is in favor of RSS. Severe respiratory involvement is usually present in RSS but is unusual in EDMD [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/40\" class=\"abstract_t\">40</a>]. Mutations in the selenoprotein N1 gene (SEPN1) have been identified in a subset of patients with RSS (RSMD1). (See <a href=\"topic.htm?path=congenital-myopathies#H12\" class=\"medical medical_review\">&quot;Congenital myopathies&quot;, section on 'Multiminicore disease'</a>.)</p><p>An Emery-Dreifuss-like phenotype with limb-girdle weakness and early onset of joint contractures, but without cardiomyopathy, is caused by mutations of the TTN gene [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/54\" class=\"abstract_t\">54</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no disease modifying therapy for EDMD. Management is supportive. Cardiomyopathy and conduction system defects are major problems, as discussed in the following section. (See <a href=\"#H12\" class=\"local\">'Cardiac issues'</a> below.)</p><p>Physical therapy should focus on stretching exercises to prevent the early development of contractures [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/17\" class=\"abstract_t\">17</a>]. Other interventions include orthopedic procedures to release contractures, spinal fusion for severe scoliosis, walking aids (eg, canes walkers, orthoses, wheelchairs) to facilitate mobility, and, rarely, respiratory aids in the late stages of the disease.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Cardiac issues</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The principal concern in the patient with EDMD is death resulting from cardiac involvement. The cardiac status of the patient should therefore be investigated, even in asymptomatic patients, with a referral for cardiology assessment at the time of diagnosis [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/55\" class=\"abstract_t\">55</a>]. Patients with autosomal dominant EDMD and X-linked recessive forms of EDMD should have annual follow-up with ECG, echocardiography, and ambulatory ECG; patients with autosomal recessive EDMD should have annual ECG and ambulatory ECG.</p><p>Cardiac intervention is required to treat arrhythmias, heart failure, and conduction defects [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/17\" class=\"abstract_t\">17</a>]. Placement of a cardiac pacemaker alone is insufficient to prevent sudden cardiac death [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/33\" class=\"abstract_t\">33</a>]. An implantable cardioverter defibrillator can be lifesaving in patients with evidence of atrioventricular block [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/56\" class=\"abstract_t\">56</a>]. Therefore, patients with EDMD and cardiac involvement require primary placement of combined pacemaker with an implantable cardiac defibrillator [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/33\" class=\"abstract_t\">33</a>]. (See <a href=\"topic.htm?path=permanent-cardiac-pacing-overview-of-devices-and-indications\" class=\"medical medical_review\">&quot;Permanent cardiac pacing: Overview of devices and indications&quot;</a> and <a href=\"topic.htm?path=implantable-cardioverter-defibrillators-overview-of-indications-components-and-functions\" class=\"medical medical_review\">&quot;Implantable cardioverter-defibrillators: Overview of indications, components, and functions&quot;</a>.)</p><p>Cardiac transplantation may be an option in selected patients with EDMD [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/57\" class=\"abstract_t\">57</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Anesthesia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Potential problems related to anesthesia should be anticipated for patients with EDMD undergoing surgery, which may be required to manage orthopedic complications of the disease [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/17,58\" class=\"abstract_t\">17,58</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cardiac pacing (temporary or permanent) should be available perioperatively.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anesthetic agents with myocardial depressant activity should be avoided in patients with significant cardiomyopathy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neck flexion may be markedly reduced, causing difficulty with endotracheal intubation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Flexion contractures of the cervical and lumbar paravertebral muscles may interfere with spinal and epidural anesthesia.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine</a> is contraindicated because patients with degenerative or dystrophic neuromuscular disease are at increased risk for the development of severe hyperkalemia.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rhabdomyolysis, hyperkalemia, or other catabolic reactions in muscle have not been described in EDMD. However, episodes that mimic malignant hyperthermia have been reported in other muscular dystrophies and neuromuscular disorders, with clinical manifestations that include rhabdomyolysis, hyperkalemia, and sudden cardiac arrest [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/59-61\" class=\"abstract_t\">59-61</a>]. Thus, we recommend avoidance of potential triggering agents such as depolarizing muscle relaxants (eg, <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a>) and volatile anesthetic drugs (eg, halothane, <a href=\"topic.htm?path=isoflurane-drug-information\" class=\"drug drug_general\">isoflurane</a>, <a href=\"topic.htm?path=desflurane-drug-information\" class=\"drug drug_general\">desflurane</a>, and <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a>).</p><p/><p class=\"headingAnchor\" id=\"H692740689\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In most cases of EDMD, muscle weakness and atrophy are slowly progressive during the first three decades of life but advance more rapidly thereafter [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/35\" class=\"abstract_t\">35</a>]. Most patients remain ambulatory for many years and seldom if ever develop profound motor or respiratory dysfunction [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/3\" class=\"abstract_t\">3</a>]. Loss of ambulation is seen more often with autosomal dominant EDMD and is unusual in X-linked EDMD [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Patients with EDMD are at risk of cardiac death from heart block and from progressive heart failure. The onset of cardiac abnormalities usually occurs in the third decade in EDMD. Earlier onset of severe involvement is rare [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/62-64\" class=\"abstract_t\">62-64</a>], but has been reported; there is a least one case of serious ventricular arrhythmia in a young patient with EDMD 1 [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/36\" class=\"abstract_t\">36</a>]. Cardiac involvement is more aggressive in EDMD 2 [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/65\" class=\"abstract_t\">65</a>]; ventricular arrhythmias occur earlier and lead to dilated cardiomyopathy [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/20,41\" class=\"abstract_t\">20,41</a>]. Sudden death can occur, more frequently in EDMD 2, but also in EDMD 1. There is no correlation between the severity of the neuromuscular involvement and the degree of cardiac abnormality [<a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/62,66,67\" class=\"abstract_t\">62,66,67</a>]. (See <a href=\"#H12\" class=\"local\">'Cardiac issues'</a> above.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=muscular-dystrophy-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Muscular dystrophy (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=overview-of-muscular-dystrophies-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Overview of muscular dystrophies (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Emery-Dreifuss muscular dystrophy (EDMD) is a genetically heterogenous disorder. The most common type is autosomal dominant EDMD caused by a heterozygous LMNA mutation, followed by X-linked EDMD caused by EMD or FHL1 mutations. (See <a href=\"#H5\" class=\"local\">'Genetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The onset of symptoms from EDMD usually occurs in the first or second decade of life. The cardinal features are early contractures, childhood onset of slowly progressive humeroperoneal muscle <span class=\"nowrap\">weakness/wasting,</span> and cardiac disease with conduction defects, arrhythmias, and cardiomyopathy. (See <a href=\"#H967340544\" class=\"local\">'Symptoms and signs'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Laboratory findings in EDMD include elevation of serum creatine kinase (typically modest but sometimes severe), electrocardiography abnormalities (eg, atrioventricular block, small T waves, atrial arrhythmias), and myopathic features on electromyography (EMG) and muscle biopsy. (See <a href=\"#H967340762\" class=\"local\">'Laboratory studies'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In cases with typical clinical features of EDMD and a supportive family history, genetic testing may confirm the diagnosis (<a href=\"image.htm?imageKey=NEURO%2F100447\" class=\"graphic graphic_algorithm graphicRef100447 \">algorithm 1</a>). In cases with early contractures that otherwise lack typical features of EDMD, the presence of myopathic changes on EMG and muscle biopsy is supportive of EDMD (<a href=\"image.htm?imageKey=PEDS%2F52444\" class=\"graphic graphic_algorithm graphicRef52444 \">algorithm 2</a>). (See <a href=\"#H9\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is no disease modifying therapy for EDMD. Management is supportive. Cardiac interventions may be required to treat arrhythmias, heart failure, and conduction defects. (See <a href=\"#H11\" class=\"local\">'Management'</a> above and <a href=\"#H12\" class=\"local\">'Cardiac issues'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Potential problems related to anesthesia should be anticipated for patients with EDMD undergoing surgery. (See <a href=\"#H13\" class=\"local\">'Anesthesia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients with EDMD remain ambulatory for many years and seldom if ever develop profound motor or respiratory dysfunction. However, loss of ambulation can occur and is seen more often with autosomal dominant EDMD than with X-linked EDMD. (See <a href=\"#H692740689\" class=\"local\">'Prognosis'</a> above.) </p><p/><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/1\" class=\"nounderline abstract_t\">Puckelwartz M, McNally EM. Emery-Dreifuss muscular dystrophy. Handb Clin Neurol 2011; 101:155.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/2\" class=\"nounderline abstract_t\">Worman HJ, Ostlund C, Wang Y. Diseases of the nuclear envelope. Cold Spring Harb Perspect Biol 2010; 2:a000760.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/3\" class=\"nounderline abstract_t\">Bonne G, Quijano-Roy S. Emery-Dreifuss muscular dystrophy, laminopathies, and other nuclear envelopathies. Handb Clin Neurol 2013; 113:1367.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/4\" class=\"nounderline abstract_t\">Yates JR, Warner JP, Smith JA, et al. Emery-Dreifuss muscular dystrophy: linkage to markers in distal Xq28. J Med Genet 1993; 30:108.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/5\" class=\"nounderline abstract_t\">Bione S, Maestrini E, Rivella S, et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet 1994; 8:323.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/6\" class=\"nounderline abstract_t\">Nagano A, Koga R, Ogawa M, et al. Emerin deficiency at the nuclear membrane in patients with Emery-Dreifuss muscular dystrophy. Nat Genet 1996; 12:254.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/7\" class=\"nounderline abstract_t\">Tsuchiya Y, Hase A, Ogawa M, et al. Distinct regions specify the nuclear membrane targeting of emerin, the responsible protein for Emery-Dreifuss muscular dystrophy. Eur J Biochem 1999; 259:859.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/8\" class=\"nounderline abstract_t\">Gueneau L, Bertrand AT, Jais JP, et al. Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2009; 85:338.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/9\" class=\"nounderline abstract_t\">Windpassinger C, Schoser B, Straub V, et al. An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1. Am J Hum Genet 2008; 82:88.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/10\" class=\"nounderline abstract_t\">Cowling BS, Cottle DL, Wilding BR, et al. Four and a half LIM protein 1 gene mutations cause four distinct human myopathies: a comprehensive review of the clinical, histological and pathological features. Neuromuscul Disord 2011; 21:237.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/11\" class=\"nounderline abstract_t\">Selcen D, Bromberg MB, Chin SS, Engel AG. Reducing bodies and myofibrillar myopathy features in FHL1 muscular dystrophy. Neurology 2011; 77:1951.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/12\" class=\"nounderline abstract_t\">Raffaele Di Barletta M, Ricci E, Galluzzi G, et al. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2000; 66:1407.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/13\" class=\"nounderline abstract_t\">Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999; 21:285.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/14\" class=\"nounderline abstract_t\">Jimenez-Escrig A, Gobernado I, Garcia-Villanueva M, Sanchez-Herranz A. Autosomal recessive Emery-Dreifuss muscular dystrophy caused by a novel mutation (R225Q) in the lamin A/C gene identified by exome sequencing. Muscle Nerve 2012; 45:605.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/15\" class=\"nounderline abstract_t\">Zhang Q, Bethmann C, Worth NF, et al. Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. Hum Mol Genet 2007; 16:2816.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/16\" class=\"nounderline abstract_t\">Liang WC, Mitsuhashi H, Keduka E, et al. TMEM43 mutations in Emery-Dreifuss muscular dystrophy-related myopathy. Ann Neurol 2011; 69:1005.</a></li><li class=\"breakAll\">Bonne G, Leturcq F, Ben Yaou R. Emery-Dreifuss muscular dystrophy. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1436/ (Accessed on March 19, 2015).</li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/18\" class=\"nounderline abstract_t\">Carboni N, Mateddu A, Marrosu G, et al. Genetic and clinical characteristics of skeletal and cardiac muscle in patients with lamin A/C gene mutations. Muscle Nerve 2013; 48:161.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/19\" class=\"nounderline abstract_t\">Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999; 341:1715.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/20\" class=\"nounderline abstract_t\">B&eacute;cane HM, Bonne G, Varnous S, et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin Electrophysiol 2000; 23:1661.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/21\" class=\"nounderline abstract_t\">Forissier JF, Bonne G, Bouchier C, et al. Apical left ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation. Eur J Heart Fail 2003; 5:821.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/22\" class=\"nounderline abstract_t\">Charniot JC, Pascal C, Bouchier C, et al. Functional consequences of an LMNA mutation associated with a new cardiac and non-cardiac phenotype. Hum Mutat 2003; 21:473.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/23\" class=\"nounderline abstract_t\">Quijano-Roy S, Mbieleu B, B&ouml;nnemann CG, et al. De novo LMNA mutations cause a new form of congenital muscular dystrophy. Ann Neurol 2008; 64:177.</a></li><li class=\"breakAll\">Darras BT. Unpublished observations, 2009.</li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/25\" class=\"nounderline abstract_t\">Komaki H, Hayashi YK, Tsuburaya R, et al. Inflammatory changes in infantile-onset LMNA-associated myopathy. Neuromuscul Disord 2011; 21:563.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/26\" class=\"nounderline abstract_t\">De Sandre-Giovannoli A, Chaouch M, Kozlov S, et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 2002; 70:726.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/27\" class=\"nounderline abstract_t\">De Sandre-Giovannoli A, Bernard R, Cau P, et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003; 300:2055.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/28\" class=\"nounderline abstract_t\">Chen L, Lee L, Kudlow BA, et al. LMNA mutations in atypical Werner's syndrome. Lancet 2003; 362:440.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/29\" class=\"nounderline abstract_t\">Navarro CL, De Sandre-Giovannoli A, Bernard R, et al. Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. Hum Mol Genet 2004; 13:2493.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/30\" class=\"nounderline abstract_t\">Muntoni F, Bonne G, Goldfarb LG, et al. Disease severity in dominant Emery Dreifuss is increased by mutations in both emerin and desmin proteins. Brain 2006; 129:1260.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/31\" class=\"nounderline abstract_t\">Ben Yaou R, Toutain A, Arimura T, et al. Multitissular involvement in a family with LMNA and EMD mutations: Role of digenic mechanism? Neurology 2007; 68:1883.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/32\" class=\"nounderline abstract_t\">Norwood FL, Harling C, Chinnery PF, et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009; 132:3175.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/33\" class=\"nounderline abstract_t\">Wicklund MP. The muscular dystrophies. Continuum (Minneap Minn) 2013; 19:1535.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/34\" class=\"nounderline abstract_t\">Emery AE. Emery-Dreifuss muscular dystrophy - a 40 year retrospective. Neuromuscul Disord 2000; 10:228.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/35\" class=\"nounderline abstract_t\">Bonne G, Mercuri E, Muchir A, et al. Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Ann Neurol 2000; 48:170.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/36\" class=\"nounderline abstract_t\">Carboni N, Mura M, Mercuri E, et al. Cardiac and muscle imaging findings in a family with X-linked Emery-Dreifuss muscular dystrophy. Neuromuscul Disord 2012; 22:152.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/37\" class=\"nounderline abstract_t\">Hopkins LC, Jackson JA, Elsas LJ. Emery-dreifuss humeroperoneal muscular dystrophy: an x-linked myopathy with unusual contractures and bradycardia. Ann Neurol 1981; 10:230.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/38\" class=\"nounderline abstract_t\">Rakovec P, Zidar J, Sinkovec M, et al. Cardiac involvement in Emery-Dreifuss muscular dystrophy: role of a diagnostic pacemaker. Pacing Clin Electrophysiol 1995; 18:1721.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/39\" class=\"nounderline abstract_t\">Sakata K, Shimizu M, Ino H, et al. High incidence of sudden cardiac death with conduction disturbances and atrial cardiomyopathy caused by a nonsense mutation in the STA gene. Circulation 2005; 111:3352.</a></li><li class=\"breakAll\">Durmus H, Serdaroglu-Oflazer P, Deymeer F. Emery-Dreifuss muscular dystrophy: nuclear envelopathies. In: Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach, 2nd ed, Darras BT, Jones HR Jr, Ryan MM, De Vivo DC (Eds), Academic Press, San Diego 2015. p.667.</li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/41\" class=\"nounderline abstract_t\">Cattin ME, Muchir A, Bonne G. 'State-of-the-heart' of cardiac laminopathies. Curr Opin Cardiol 2013; 28:297.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/42\" class=\"nounderline abstract_t\">Vytopil M, Benedetti S, Ricci E, et al. Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomuscular phenotypes. J Med Genet 2003; 40:e132.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/43\" class=\"nounderline abstract_t\">Finsterer J, St&ouml;llberger C, Sehnal E, et al. Dilated, arrhythmogenic cardiomyopathy in emery-dreifuss muscular dystrophy due to the emerin splice-site mutation c.449 + 1G&gt;A. Cardiology 2015; 130:48.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/44\" class=\"nounderline abstract_t\">Bialer MG, Bruns DE, Kelly TE. Muscle enzymes and isoenzymes in Emery-Dreifuss muscular dystrophy. Clin Chem 1990; 36:427.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/45\" class=\"nounderline abstract_t\">Yates JR, Wehnert M. The Emery-Dreifuss Muscular Dystrophy Mutation Database. Neuromuscul Disord 1999; 9:199.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/46\" class=\"nounderline abstract_t\">Manilal S, Sewry CA, Man N, et al. Diagnosis of X-linked Emery-Dreifuss muscular dystrophy by protein analysis of leucocytes and skin with monoclonal antibodies. Neuromuscul Disord 1997; 7:63.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/47\" class=\"nounderline abstract_t\">Mora M, Cartegni L, Di Blasi C, et al. X-linked Emery-Dreifuss muscular dystrophy can be diagnosed from skin biopsy or blood sample. Ann Neurol 1997; 42:249.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/48\" class=\"nounderline abstract_t\">Merlini L. Selectivity of muscle sparing in Emery-Dreifuss muscular dystrophy. Neuromuscul Disord 2009; 19:500.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/49\" class=\"nounderline abstract_t\">Carboni N, Mura M, Marrosu G, et al. Muscle imaging analogies in a cohort of patients with different clinical phenotypes caused by LMNA gene mutations. Muscle Nerve 2010; 41:458.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/50\" class=\"nounderline abstract_t\">Menache CC, Brown CA, Donnelly JH, et al. Identification of a novel truncating mutation (S171X) in the Emerin gene in five members of a Caucasian American family with Emery-Dreifuss muscular dystrophy. Hum Mutat 2000; 16:94.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/51\" class=\"nounderline abstract_t\">Brown CA, Lanning RW, McKinney KQ, et al. Novel and recurrent mutations in lamin A/C in patients with Emery-Dreifuss muscular dystrophy. Am J Med Genet 2001; 102:359.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/52\" class=\"nounderline abstract_t\">Dubowitz V. Rigid spine syndrome: a muscle syndrome in search of a name. Proc R Soc Med 1973; 66:219.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/53\" class=\"nounderline abstract_t\">Finsterer J, Ramaciotti C, Wang CH, et al. Cardiac findings in congenital muscular dystrophies. Pediatrics 2010; 126:538.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/54\" class=\"nounderline abstract_t\">De Cid R, Ben Yaou R, Roudaut C, et al. A new titinopathy: Childhood-juvenile onset Emery-Dreifuss-like phenotype without cardiomyopathy. Neurology 2015; 85:2126.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/55\" class=\"nounderline abstract_t\">Feingold B, Mahle WT, Auerbach S, et al. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation 2017; 136:e200.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/56\" class=\"nounderline abstract_t\">Golzio PG, Chiribiri A, Gaita F. 'Unexpected' sudden death avoided by implantable cardioverter defibrillator in Emery Dreifuss patient. Europace 2007; 9:1158.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/57\" class=\"nounderline abstract_t\">Dell'Amore A, Botta L, Martin Suarez S, et al. Heart transplantation in patients with Emery-Dreifuss muscular dystrophy: case reports. Transplant Proc 2007; 39:3538.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/58\" class=\"nounderline abstract_t\">Aldwinckle RJ, Carr AS. The anesthetic management of a patient with Emery-Dreifuss muscular dystrophy for orthopedic surgery. Can J Anaesth 2002; 49:467.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/59\" class=\"nounderline abstract_t\">Takagi A, Nakase H. [Malignant hyperthermia-like reactions in Duchenne or Becker muscular dystrophy: review and hypothesis]. Rinsho Shinkeigaku 2008; 48:101.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/60\" class=\"nounderline abstract_t\">Wedel DJ. Malignant hyperthermia and neuromuscular disease. Neuromuscul Disord 1992; 2:157.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/61\" class=\"nounderline abstract_t\">Heiman-Patterson TD, Natter HM, Rosenberg HR, et al. Malignant hyperthermia susceptibility in X-linked muscle dystrophies. Pediatr Neurol 1986; 2:356.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/62\" class=\"nounderline abstract_t\">Voit T, Krogmann O, Lenard HG, et al. Emery-Dreifuss muscular dystrophy: disease spectrum and differential diagnosis. Neuropediatrics 1988; 19:62.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/63\" class=\"nounderline abstract_t\">Buckley AE, Dean J, Mahy IR. Cardiac involvement in Emery Dreifuss muscular dystrophy: a case series. Heart 1999; 82:105.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/64\" class=\"nounderline abstract_t\">Dickey RP, Ziter FA, Smith RA. Emery-Dreifuss muscular dystrophy. J Pediatr 1984; 104:555.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/65\" class=\"nounderline abstract_t\">Taylor MR, Fain PR, Sinagra G, et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 2003; 41:771.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/66\" class=\"nounderline abstract_t\">Bialer MG, McDaniel NL, Kelly TE. Progression of cardiac disease in Emery-Dreifuss muscular dystrophy. Clin Cardiol 1991; 14:411.</a></li><li><a href=\"https://www.uptodate.com/contents/emery-dreifuss-muscular-dystrophy/abstract/67\" class=\"nounderline abstract_t\">Waters DD, Nutter DO, Hopkins LC, Dorney ER. Cardiac features of an unusual X-linked humeroperoneal neuromuscular disease. N Engl J Med 1975; 293:1017.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6185 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H15\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">GENETICS</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">X-linked forms</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Autosomal dominant and recessive forms</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Laminopathies</a></li></ul></li><li><a href=\"#H692738139\" id=\"outline-link-H692738139\">EPIDEMIOLOGY</a></li><li><a href=\"#H967340517\" id=\"outline-link-H967340517\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H967340544\" id=\"outline-link-H967340544\">Symptoms and signs</a></li><li><a href=\"#H967340762\" id=\"outline-link-H967340762\">Laboratory studies</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">DIAGNOSIS</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">Differential diagnosis</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">MANAGEMENT</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Cardiac issues</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Anesthesia</a></li></ul></li><li><a href=\"#H692740689\" id=\"outline-link-H692740689\">PROGNOSIS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H14\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/6185|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/100447\" class=\"graphic graphic_algorithm\">- Evaluation of a child with EDMD phenotype</a></li><li><a href=\"image.htm?imageKey=PEDS/52444\" class=\"graphic graphic_algorithm\">- Evaluation of early contractures</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-myopathies\" class=\"medical medical_review\">Congenital myopathies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=duchenne-and-becker-muscular-dystrophy-clinical-features-and-diagnosis\" class=\"medical medical_review\">Duchenne and Becker muscular dystrophy: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=facioscapulohumeral-muscular-dystrophy\" class=\"medical medical_review\">Facioscapulohumeral muscular dystrophy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=implantable-cardioverter-defibrillators-overview-of-indications-components-and-functions\" class=\"medical medical_review\">Implantable cardioverter-defibrillators: Overview of indications, components, and functions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=limb-girdle-muscular-dystrophy\" class=\"medical medical_review\">Limb-girdle muscular dystrophy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lipodystrophic-syndromes\" class=\"medical medical_review\">Lipodystrophic syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=myotonic-dystrophy-etiology-clinical-features-and-diagnosis\" class=\"medical medical_review\">Myotonic dystrophy: Etiology, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oculopharyngeal-distal-and-congenital-muscular-dystrophies\" class=\"medical medical_review\">Oculopharyngeal, distal, and congenital muscular dystrophies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=muscular-dystrophy-the-basics\" class=\"medical medical_basics\">Patient education: Muscular dystrophy (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-muscular-dystrophies-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Overview of muscular dystrophies (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=permanent-cardiac-pacing-overview-of-devices-and-indications\" class=\"medical medical_review\">Permanent cardiac pacing: Overview of devices and indications</a></li></ul></div></div>","javascript":null}